Amogene (Xiamen) Biotechnology Co., Ltd.

Time frame: 1 February 2023 - 31 January 2024

Region or country/territory

Sector

Subject or journal group

Article ‘Count’ and ‘Share’ for Amogene (Xiamen) Biotechnology Co., Ltd. based on listed parameters only.

The articles listed below published by authors from Amogene (Xiamen) Biotechnology Co., Ltd., organized by journal and article, represent the research output in Count and Share according to the parameters selected above.

Journal	Count	Share
Developmental Cell	1	0.03
Proceedings of the National Academy of Sciences of the United States of America	1	0.04

Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Latest supplement

Nature Index 2024 Health Sciences

More money is being spent on medical R&D than ever before, but with few new drugs to show for it. The race is on to find technological solutions that will speed up drug development and deliver better clinical outcomes. Nature Index Health Sciences 2024 highlights the people and projects that are bringing fresh perspectives to some of the most complex challenges in medicine and provides an in-depth look at how one country – the United States – is dominating the field.

Access free

Nature Strategy Reports

Comprehensive deep-dives and custom high-quality reports into relevant research topics to influence major research and funding decisions.

Learn more

Nature Navigator

One centralised, holistic source of research trends to track emerging research topics and guide your decision making.

Learn more